Geovax Labs Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)2.77 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.32Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $2.9M Enterprise Value −$213.4K Shares Outstanding 9.1M diluted Next Earnings Date16 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary GeoVax Labs is at a critical operational inflection point. The company has strategically prioritized its portfolio to focus on its lead clinical programs: GEO-MVA (a next-generation Mpox/smallpox vaccine) and Gedeptin (a gene-directed enzyme prodrug therapy for solid tumors), while discontinuing its COVID-19 vaccine candidate (GEO-CM04S1). While the regulatory pathway for GEO-MVA has been streamlined by favorable EMA scientific advice—allowing GeoVax to proceed directly to a single pivotal Phase 3 immunobridging trial—the company faces severe liquidity constraints. With only $1.3 million in cash as of March 31, 2026, and a persistent going concern warning, the near-term outlook is highly dependent on dilutive capital raises or securing strategic partnerships. Consequently, a Hold rating is recommended until financing risk is mitigated and Phase 3 execution begins. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$10.00 Mean target$10.00 High · most bullish analyst$10.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.5020% The company fails to secure sufficient capital to initiate the Phase 3 trial of GEO-MVA, leading to severe clinical delays or further program suspensions. Continued heavy dilution from warrant exercises depresses the share price, and the going concern status escalates toward restructuring or insolvency. Base CaseCentral scenario $1.5055% GeoVax initiates the GEO-MVA Phase 3 trial in late 2026 but experiences typical clinical startup delays. The company continues to fund operations through highly dilutive warrant inducements and PIPE offerings, keeping the stock price range-bound due to ongoing share supply expansion. Gedeptin remains on track for a Phase 2 trial in 2027. Bull CaseUpside scenario $4.7425% GEO-MVA successfully initiates its Phase 3 trial in H2 2026 with rapid enrollment, supported by global demand for Mpox vaccine supply resilience. The company secures a non-dilutive government contract or a high-value strategic partnership, resolving its going concern status. Gedeptin combination trials with immune checkpoint inhibitors show strong efficacy, driving significant upward re-rating. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |